Panax GinsengvsRhodiola Rosea

Ginsenosides (Rb1, Rg1, Rg3, Re, and others) have diverse pharmacological actions. They modulate the hypothalamic-pituitary-adrenal (HPA) axis, reducing cortisol release under stress through glucocorticoid receptor modulation. Ginsenosides inhibit acetylcholinesterase (AChE), increasing acetylcholine levels in the hippocampus and enhancing muscarinic and nicotinic receptor function. They enhance nitric oxide production via endothelial nitric oxide synthase (eNOS) for cerebral vasodilation. Rb1 and Rg1 promote BDNF and NGF expression through activation of CREB and TrkB/TrkA signaling, supporting neuroplasticity. Rg1 specifically enhances hippocampal neurogenesis via the PI3K/Akt pathway and Wnt/β-catenin signaling, and improves spatial learning in animal models. Ginsenosides may also modulate GABA-A receptors and have antioxidant properties.

Rhodiola modulates the hypothalamic-pituitary-adrenal (HPA) axis and reduces cortisol release under stress, possibly through modulation of glucocorticoid receptor sensitivity. Salidroside and rosavins inhibit catechol-O-methyltransferase (COMT) and monoamine oxidase A and B (MAO-A, MAO-B), slowing the breakdown of dopamine, serotonin, and norepinephrine in the brain — increasing catecholamine availability in the prefrontal cortex and limbic system during stress. Rhodiola activates AMP-activated protein kinase (AMPK), a cellular energy sensor that enhances glucose uptake and mitochondrial biogenesis. It has antioxidant effects via activation of Nrf2 and HO-1, protecting neurons from stress-induced oxidative damage. Salidroside may also modulate opioid peptide (beta-endorphin) release and enhance nitric oxide production.